Stockreport

resTORbio Announces Additional RTB101 Phase 2b Data Demonstrating Decreased Incidence of Laboratory-Confirmed RTIs with Severe Symptoms, Total Infections and UTIs

RESTORBIO  (TORC) 
Last restorbio earnings: 3/12 07:30 am Check Earnings Report
PDF RTB101 10 mg once daily decreased incidence of laboratory-confirmed respiratory tract infections (RTIs) with severe symptoms by 52.1% vs. placebo (p=0.034) In addition [Read more]